Press Releases
  Date Title View
May 4, 2017
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that Novartis has exercised its option to an exclusive license for the global development and commercialization of emricasan, the company's first-in-class, orally-active pan-caspase inhibitor, under terms of the Option, Collabo...
Apr 27, 2017
SAN DIEGO, April 27, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the first quarter ended March 31, 2017, after the market close on Thursday, May 4, 2017. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Thursday, M...
Apr 21, 2017
AMSTERDAM, the Netherlands, April 21, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that two posters co-authored by Conatus employees are being presented today at The International Liver Congress™ 2017, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Amsterd...
Mar 27, 2017
SAN DIEGO, March 27, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the company's scheduled presentations at two upcoming investor conferences in New York: H.C. Wainwright NASH Investor Conference at 2:20 p.m. ET on Monday, April 3. 16...
Mar 15, 2017
SAN DIEGO, March 15, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2016, and provided updates on its clinical development programs. Conatus is developing emricasan, its first-in-class, orally active pan-caspase inhibit...
Mar 8, 2017
SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2016, after the market close on Wednesday, March 15, 2017. Conatus will host a conference call and audio webcast at 4:30 p.m. Eas...
Feb 7, 2017
SAN DIEGO, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the appointment of William R. LaRue as an additional independent member to the Conatus Board of Directors. Mr. LaRue also will serve as Chair of the Audit Committee. "We are pleased to strengthen our Board of Dir...
Feb 6, 2017
SAN DIEGO, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Biotechnology Industry Organization (BIO) CEO & Investor Conference in New York at 2:30 p.m. ET on Monday, February 13, 2017. An ...
Feb 2, 2017
SAN DIEGO , Feb. 02, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) announced today the promotion of Daniel L. Ripley to Senior Vice President, Business Development, Program and Alliance Management, effective immediately. Mr. Ripley will continue to lead licensing and partnering initiatives and act...
Dec 19, 2016
- Conference Call and Webcast Presentation at 5:30 p.m. ET Today - - Continuing Initial Focus on NASH Cirrhosis with Parallel Development in NASH Fibrosis - - Full Funding in Position for Remaining Development of E...
FirstPrevious
2
...
NextLast
= add release to Briefcase